A lipoprotein lipase activator, NO-1886 prevents impaired endothelium-dependent relaxation of aorta caused by exercise in aged rats.
Exercise decreases plasma total cholesterol and triglycerides, and simultaneously, increases high density lipoprotein (HDL) cholesterol. As a result, exercise is believed to aid in preventing atherosclerosis. However, we do not know whether exercise protects against the development of atherosclerosis in the elderly. The aim of this study was to ascertain whether the lipoprotein lipase activator NO-1886 had an effect on the prevention of atherosclerosis in aged rats which undergo exercise. Exercise for 3 months did not affect plasma lipids but decreased the accumulation of visceral fat in 2-year-old rats (aged rat). Exercise also resulted in an elevation of plasma lipid peroxide (LPO) levels and impaired the endothelium-dependent relaxation of the thoracic aorta caused by acetylcholine in aged rats. On the other hand, NO-1886 decreased plasma triglycerides and increased HDL cholesterol and suppressed the elevation of plasma LPO levels caused by exercise. Furthermore, NO-1886 prevented impaired endothelium-dependent relaxation caused by exercise. In summary, the results of our study indicate that exercise may cause impaired endothelium-dependent relaxation by elevation of LPO in aged rats, and that NO-1886 prevents this impaired endothelium-dependent relaxation of aorta by reducing plasma triglycerides, elevating HDL cholesterol, and suppressing the elevation of plasma LPO caused by exercise.
Kusunoki
Masataka
M
The First Department of Internal Medicine, Aichi Medical University, Nagakute-cho, Aichi-gun, Japan. kusunoki@aichi-med-u.ac.jp
Tsutsumi
Kazuhiko
K
Hara
Tsutomu
T
Ogawa
Hitoshi
H
Nakamura
Takao
T
Miyata
Tetsuro
T
Sakakibara
Fumihiko
F
Fukuzawa
Yoshitaka
Y
Suga
Takashi
T
Kakumu
Shinich
S
Nakaya
Yutaka
Y
D000375:Aging / Q000502:physiology*; D000818:Animals; D001011:Aorta / Q000502:physiology*; D001549:Benzamides / Q000494:pharmacology*; D001835:Body Weight; D004435:Eating; D004730:Endothelium, Vascular / Q000502:physiology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D015227:Lipid Peroxidation / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008071:Lipoprotein Lipase / Q000187:drug effects*; D008297:Male; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D010805:Physical Conditioning, Animal; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000378:metabolism; D014664:Vasodilation / Q000187:drug effects*
D001549:Benzamides; D000960:Hypolipidemic Agents; D008055:Lipids; D009943:Organophosphorus Compounds; C082137:4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide; D013482:Superoxide Dismutase; D008071:Lipoprotein Lipase